MARSHALL WACE, LLP - TURNING POINT THERAPEUTICS I ownership

TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 1 filers reported holding TURNING POINT THERAPEUTICS I in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of TURNING POINT THERAPEUTICS I
ValueSharesWeighting
Q2 2022$22,309,000
+1296.1%
296,462
+2160.5%
0.05%
+411.1%
Q4 2020$1,598,000
+40.2%
13,115
+0.5%
0.01%
+28.6%
Q3 2020$1,140,000
+35.2%
13,0520.0%0.01%
+16.7%
Q2 2020$843,000
+360.7%
13,052
+218.4%
0.01%
+200.0%
Q1 2020$183,0004,0990.00%
Other shareholders
TURNING POINT THERAPEUTICS I shareholders Q3 2022
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 2,392,297$291,501,0006.94%
Burrage Capital Management LLC 72,484$8,832,0006.73%
MPM BioImpact LLC 617,372$75,226,0006.50%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 113,541$13,816,0003.77%
Orbimed Advisors 2,745,327$334,518,0002.93%
SECTORAL ASSET MANAGEMENT INC 257,379$31,362,0002.21%
Parkman Healthcare Partners LLC 59,377$7,235,0001.85%
Nicholas Investment Partners, LP 183,676$22,381,0001.73%
EMERALD ADVISERS, LLC 357,038$43,505,0001.44%
EMERALD MUTUAL FUND ADVISERS TRUST 336,173$40,963,0001.42%
View complete list of TURNING POINT THERAPEUTICS I shareholders